Current Strategies of Therapy in Alzheimer`s Disease

The molecular mechanisms involved in the plaques and tangles pathogenesis in Alzheimer`s disease (AD) discloses new potential targets for therapies that could modify the clinical course. In the last years, the neurotransmission defect (cholinergic hypothesis) has been extensively investigated. Choli...

Full description

Saved in:
Bibliographic Details
Published in:The open neuropsychopharmacology journal 2008-12, Vol.1 (1), p.19-23
Main Authors: Martocchia, A., Falaschi, P.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1260-e9ec6ec87a4fb7ed41ea94efd5dda07c76fc9445c46c7f3112f18484d6df87e33
cites
container_end_page 23
container_issue 1
container_start_page 19
container_title The open neuropsychopharmacology journal
container_volume 1
creator Martocchia, A.
Falaschi, P.
description The molecular mechanisms involved in the plaques and tangles pathogenesis in Alzheimer`s disease (AD) discloses new potential targets for therapies that could modify the clinical course. In the last years, the neurotransmission defect (cholinergic hypothesis) has been extensively investigated. Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and N-methyl-D-aspartate receptor antagonist (memantine) are approved agents that can delay the cognitive deterioration. Recent evidence in the literature suggests innovative strategies of treatment in AD, acting at the level of the amyloid cascade that is related to the neuronal defects and the neurotransmission disturbances. Confirmatory data are necessary and they will arise from the clinical trials with these potential disease- modifying drugs.
doi_str_mv 10.2174/1876523800801010019
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744697480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>744697480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1260-e9ec6ec87a4fb7ed41ea94efd5dda07c76fc9445c46c7f3112f18484d6df87e33</originalsourceid><addsrcrecordid>eNptkD1PwzAYhC0EEqXwC1i8MQXs-I3tjFX4lCoxUGZj7Nc0KF_YyVB-PY3KwIBuuNOj0w1HyCVn1zlXcMO1kkUuNGOa8b0YL4_IYqbZjI__5FNyltInY7LgOVsQqKYYsRvpyxjtiB81JtoHutlitMOO1h1dNd9brFuMb4ne1gltwnNyEmyT8OLXl-T1_m5TPWbr54enarXOHM8ly7BEJ9FpZSG8K_TA0ZaAwRfeW6acksGVAIUD6VQQnOeBa9DgpQ9aoRBLcnXYHWL_NWEaTVsnh01jO-ynZBSALBVotm-KQ9PFPqWIwQyxbm3cGc7MfJH55yLxAxRiWKU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>744697480</pqid></control><display><type>article</type><title>Current Strategies of Therapy in Alzheimer`s Disease</title><source>Bentham Science Publishers OA</source><creator>Martocchia, A. ; Falaschi, P.</creator><creatorcontrib>Martocchia, A. ; Falaschi, P.</creatorcontrib><description>The molecular mechanisms involved in the plaques and tangles pathogenesis in Alzheimer`s disease (AD) discloses new potential targets for therapies that could modify the clinical course. In the last years, the neurotransmission defect (cholinergic hypothesis) has been extensively investigated. Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and N-methyl-D-aspartate receptor antagonist (memantine) are approved agents that can delay the cognitive deterioration. Recent evidence in the literature suggests innovative strategies of treatment in AD, acting at the level of the amyloid cascade that is related to the neuronal defects and the neurotransmission disturbances. Confirmatory data are necessary and they will arise from the clinical trials with these potential disease- modifying drugs.</description><identifier>ISSN: 1876-5238</identifier><identifier>EISSN: 1876-5238</identifier><identifier>DOI: 10.2174/1876523800801010019</identifier><language>eng</language><ispartof>The open neuropsychopharmacology journal, 2008-12, Vol.1 (1), p.19-23</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1260-e9ec6ec87a4fb7ed41ea94efd5dda07c76fc9445c46c7f3112f18484d6df87e33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3740,27924,27925</link.rule.ids></links><search><creatorcontrib>Martocchia, A.</creatorcontrib><creatorcontrib>Falaschi, P.</creatorcontrib><title>Current Strategies of Therapy in Alzheimer`s Disease</title><title>The open neuropsychopharmacology journal</title><description>The molecular mechanisms involved in the plaques and tangles pathogenesis in Alzheimer`s disease (AD) discloses new potential targets for therapies that could modify the clinical course. In the last years, the neurotransmission defect (cholinergic hypothesis) has been extensively investigated. Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and N-methyl-D-aspartate receptor antagonist (memantine) are approved agents that can delay the cognitive deterioration. Recent evidence in the literature suggests innovative strategies of treatment in AD, acting at the level of the amyloid cascade that is related to the neuronal defects and the neurotransmission disturbances. Confirmatory data are necessary and they will arise from the clinical trials with these potential disease- modifying drugs.</description><issn>1876-5238</issn><issn>1876-5238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNptkD1PwzAYhC0EEqXwC1i8MQXs-I3tjFX4lCoxUGZj7Nc0KF_YyVB-PY3KwIBuuNOj0w1HyCVn1zlXcMO1kkUuNGOa8b0YL4_IYqbZjI__5FNyltInY7LgOVsQqKYYsRvpyxjtiB81JtoHutlitMOO1h1dNd9brFuMb4ne1gltwnNyEmyT8OLXl-T1_m5TPWbr54enarXOHM8ly7BEJ9FpZSG8K_TA0ZaAwRfeW6acksGVAIUD6VQQnOeBa9DgpQ9aoRBLcnXYHWL_NWEaTVsnh01jO-ynZBSALBVotm-KQ9PFPqWIwQyxbm3cGc7MfJH55yLxAxRiWKU</recordid><startdate>20081216</startdate><enddate>20081216</enddate><creator>Martocchia, A.</creator><creator>Falaschi, P.</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20081216</creationdate><title>Current Strategies of Therapy in Alzheimer`s Disease</title><author>Martocchia, A. ; Falaschi, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1260-e9ec6ec87a4fb7ed41ea94efd5dda07c76fc9445c46c7f3112f18484d6df87e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martocchia, A.</creatorcontrib><creatorcontrib>Falaschi, P.</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>The open neuropsychopharmacology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martocchia, A.</au><au>Falaschi, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Strategies of Therapy in Alzheimer`s Disease</atitle><jtitle>The open neuropsychopharmacology journal</jtitle><date>2008-12-16</date><risdate>2008</risdate><volume>1</volume><issue>1</issue><spage>19</spage><epage>23</epage><pages>19-23</pages><issn>1876-5238</issn><eissn>1876-5238</eissn><abstract>The molecular mechanisms involved in the plaques and tangles pathogenesis in Alzheimer`s disease (AD) discloses new potential targets for therapies that could modify the clinical course. In the last years, the neurotransmission defect (cholinergic hypothesis) has been extensively investigated. Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and N-methyl-D-aspartate receptor antagonist (memantine) are approved agents that can delay the cognitive deterioration. Recent evidence in the literature suggests innovative strategies of treatment in AD, acting at the level of the amyloid cascade that is related to the neuronal defects and the neurotransmission disturbances. Confirmatory data are necessary and they will arise from the clinical trials with these potential disease- modifying drugs.</abstract><doi>10.2174/1876523800801010019</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1876-5238
ispartof The open neuropsychopharmacology journal, 2008-12, Vol.1 (1), p.19-23
issn 1876-5238
1876-5238
language eng
recordid cdi_proquest_miscellaneous_744697480
source Bentham Science Publishers OA
title Current Strategies of Therapy in Alzheimer`s Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A47%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Strategies%20of%20Therapy%20in%20Alzheimer%60s%20Disease&rft.jtitle=The%20open%20neuropsychopharmacology%20journal&rft.au=Martocchia,%20A.&rft.date=2008-12-16&rft.volume=1&rft.issue=1&rft.spage=19&rft.epage=23&rft.pages=19-23&rft.issn=1876-5238&rft.eissn=1876-5238&rft_id=info:doi/10.2174/1876523800801010019&rft_dat=%3Cproquest_cross%3E744697480%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1260-e9ec6ec87a4fb7ed41ea94efd5dda07c76fc9445c46c7f3112f18484d6df87e33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=744697480&rft_id=info:pmid/&rfr_iscdi=true